SOCRA CCRP EXAM PREP (ACTUAL EXAM)
QUESTIONS WITH VERY ELABORATED
ANSWERS CORRECTRY WELL ORGANIZED
LATEST 2024 – 2025 ALREADY GRADED A+
A _____________ ________ __________ is defined as any experience that
suggests a significant hazard, contraindication, side effect or precaution.
Has one or more of the following outcomes: Fatal Life-threatening Requires or
prolongs inpatient hospitalization Results in persistent or significant disability or
incapacity A congenital anomaly. - ANSWERS-Serious adverse event (SAE)
A _______ __________ _________is an AE for which a causal relationship to the
investigational product is at least a reasonable possibility, i.e. -a causal
relationship can not be ruled out. - ANSWERS-Suspected adverse reaction
An ___________ ______ _______ ___ ________ _______ is one that is not
identified in nature, severity or frequency in the current Investigator's Brochure.
Nature: the event has not been reported previously
Severity: prior reports were of mild intensity, but the current event is of moderate
or severe intensity
,Frequency: In the Investigator's Brochure, frequency was 1%, but has increased to
5% in current study - ANSWERS-Unexpected adverse event or adverse reaction
A _____ ___ ____________ ____ ____________is an adverse reaction that is both
serious and unexpected. - ANSWERS-Suspected and unexpected adverse reaction
(SUSAR)
Who notifies the FDA of any adverse events associated with the use of a drug that
are both serious and unexpected? - ANSWERS-Sponsor
When must the FDA be notified of a SUSAR? - ANSWERS-15 CALENDAR days after
Sponsor's initial notification.
CFR 21 Part 11 is in regard to____ - ANSWERS-Electronic records, electronic
signatures
CFR 21 Part 50 is in regard to ___ - ANSWERS-Informed Consent
CFR 21 Part 54 is in regard to___ - ANSWERS-Financial Disclosure
CFR 21 Part 56 is in regard to___ - ANSWERS-Institutional Review Boards (IRBs)
CFR 21 Part 312 is in regard to___ - ANSWERS-Investigational New Drug
Application (IND)
, CFR 21 Part 314 is in regard to___ - ANSWERS-New Drug Application (NDA)
CFR 21 Part 812 is in regard to___ - ANSWERS-Investigational Device Exemption
(IDE)
CFR 21 Part 814 is in regard to___ - ANSWERS-Premarket Approval of Medical
Devices (PMAMD)
CFR 45 Part 46 is in regard to___ - ANSWERS-Federal Research
45 CFR 46 Part A Common Rule - ANSWERS-HHS regulations for PROTECTION OF
HUMAN SUBJECTS in research
ICH E series covers: - ANSWERS-Efficacy Guidelines
ICH E2A covers: - ANSWERS-Clinical Safety Data Management
ICH E3 covers: - ANSWERS-Clinical Study Reporting
ICH E6 covers: - ANSWERS-Good Clinical Practice (GCP)
ICH E7 covers: - ANSWERS-Geriatric Populations
Los beneficios de comprar resúmenes en Stuvia estan en línea:
Garantiza la calidad de los comentarios
Compradores de Stuvia evaluaron más de 700.000 resúmenes. Así estas seguro que compras los mejores documentos!
Compra fácil y rápido
Puedes pagar rápidamente y en una vez con iDeal, tarjeta de crédito o con tu crédito de Stuvia. Sin tener que hacerte miembro.
Enfócate en lo más importante
Tus compañeros escriben los resúmenes. Por eso tienes la seguridad que tienes un resumen actual y confiable.
Así llegas a la conclusión rapidamente!
Preguntas frecuentes
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
100% de satisfacción garantizada: ¿Cómo funciona?
Nuestra garantía de satisfacción le asegura que siempre encontrará un documento de estudio a tu medida. Tu rellenas un formulario y nuestro equipo de atención al cliente se encarga del resto.
Who am I buying this summary from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller NurseLNJ. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy this summary for $13.99. You're not tied to anything after your purchase.
